{"id":52,"date":"2023-08-22T02:05:00","date_gmt":"2023-08-22T02:05:00","guid":{"rendered":"https:\/\/staging.vantagebiotrials.com\/?page_id=52"},"modified":"2026-08-13T18:53:43","modified_gmt":"2026-08-13T18:53:43","slug":"case-studies","status":"publish","type":"page","link":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/","title":{"rendered":"Case Studies"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"52\" class=\"elementor elementor-52\">\n\t\t\t\t\t\t<div class=\"elementor-section elementor-top-section elementor-element elementor-element-8afe09e elementor-section-full_width elementor-section-stretched elementor-section-height-default elementor-section-height-default cms-remove-row-no cms-section-no-padding-no cms-full-content-with-space-none cms-boxed-bg-false cms-section-boxed-divider-false cms-overlay-gradient-bg-yes cms-overlay-gradient-mode-tb\" data-id=\"8afe09e\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\r\n\t\t\t<div class=\"cms-overlay-gradient\"><\/div><div class=\"cms-section-boxed-bg\"><\/div><div class=\"cms-section-boxed-divider\"><\/div><div class=\"cms-elementor-section-remove\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-top\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-bottom\"><\/div>\t\t\t<div class=\"elementor-container elementor-column-gap-no \" >\r\n\t\t\t        <div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-faa2601\" data-id=\"faa2601\" data-element_type=\"column\" data-e-type=\"column\">\r\n            <div class=\"elementor-widget-wrap elementor-element-populated\">\r\n                \t\t<div class=\"elementor-element elementor-element-0be1123 elementor-widget elementor-widget-slider_revolution\" data-id=\"0be1123\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"slider_revolution.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\n\t\t<div class=\"wp-block-themepunch-revslider\">\n\t\t\t<!-- START casestudies REVOLUTION SLIDER 6.7.18 --><p class=\"rs-p-wp-fix\"><\/p>\n\t\t\t<rs-module-wrap id=\"rev_slider_9_1_wrapper\" data-source=\"gallery\" style=\"visibility:hidden;background:transparent;padding:0;margin:0px auto;margin-top:0;margin-bottom:0;\">\n\t\t\t\t<rs-module id=\"rev_slider_9_1\" style=\"\" data-version=\"6.7.18\">\n\t\t\t\t\t<rs-slides style=\"overflow: hidden; position: absolute;\">\n\t\t\t\t\t\t<rs-slide style=\"position: absolute;\" data-key=\"rs-11\" data-title=\"Slide\" data-in=\"o:1;\" data-out=\"o:1;\">\n\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" src=\"\/\/vantagebiotrials.com\/wp-content\/plugins\/revslider\/sr6\/assets\/assets\/dummy.png\" alt=\"\" title=\"ThinkstockPhotos-sb10065850n-001.jpg\" width=\"2000\" height=\"1333\" class=\"rev-slidebg tp-rs-img rs-lazyload\" data-lazyload=\"\/\/vantagebiotrials.com\/wp-content\/uploads\/revslider\/case-studies-fr\/ThinkstockPhotos-sb10065850n-001.jpg\" data-parallax=\"5\" data-no-retina>\n<!--\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-9-slide-11-layer-5\" \n\t\t\t\t\t\t\t\tdata-type=\"image\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:-327px;y:-68px;\"\n\t\t\t\t\t\t\t\tdata-text=\"l:22;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:1348px;h:633px;\"\n\t\t\t\t\t\t\t\tdata-frame_0=\"tp:600;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"tp:600;e:power2.inOut;st:1410;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;tp:600;e:nothing;st:w;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:5;\"\n\t\t\t\t\t\t\t><img decoding=\"async\" src=\"\/\/vantagebiotrials.com\/wp-content\/plugins\/revslider\/sr6\/assets\/assets\/dummy.png\" alt=\"\" class=\"tp-rs-img rs-lazyload\" width=\"1348\" height=\"633\" data-lazyload=\"\/\/vantagebiotrials.com\/wp-content\/uploads\/revslider\/slider-ihr-1\/cloud.png\" data-no-retina> \n\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-9-slide-11-layer-2\" \n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"rgba(51,51,51,1)\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:88px;y:162px;\"\n\t\t\t\t\t\t\t\tdata-text=\"s:40;l:40;fw:700;\"\n\t\t\t\t\t\t\t\tdata-frame_0=\"x:50px;tp:600;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"tp:600;e:easeOutExpo;st:700;sp:1000;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;tp:600;e:nothing;st:w;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:6;font-family:'Poppins';text-transform:uppercase;\"\n\t\t\t\t\t\t\t>The Science of Accuracy. \n\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-9-slide-11-layer-3\" \n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"rgba(51,51,51,1)\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:87px;y:212px;\"\n\t\t\t\t\t\t\t\tdata-text=\"s:18;l:25;fw:700;\"\n\t\t\t\t\t\t\t\tdata-frame_0=\"y:50px;tp:600;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"tp:600;e:easeOutExpo;st:900;sp:700;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;tp:600;e:nothing;st:w;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:7;font-family:'Lato';\"\n\t\t\t\t\t\t\t>\"The only source of knowledge is experience.\"<br \/>\n  - Albert Einstein \n\t\t\t\t\t\t\t<\/rs-layer><!--\n-->\t\t\t\t\t<\/rs-slide>\n\t\t\t\t\t<\/rs-slides>\n\t\t\t\t<\/rs-module>\n\t\t\t\t<script>\n\t\t\t\t\tsetREVStartSize({c: 'rev_slider_9_1',rl:[1240,1024,778,480],el:[],gw:[1349],gh:[508],type:'standard',justify:'',layout:'fullwidth',mh:\"0\"});if (window.RS_MODULES!==undefined && window.RS_MODULES.modules!==undefined && window.RS_MODULES.modules[\"revslider91\"]!==undefined) {window.RS_MODULES.modules[\"revslider91\"].once = false;window.revapi9 = undefined;if (window.RS_MODULES.checkMinimal!==undefined) window.RS_MODULES.checkMinimal()}\n\t\t\t\t<\/script>\n\t\t\t<\/rs-module-wrap>\n\t\t\t<!-- END REVOLUTION SLIDER -->\n<\/div>\n\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t            <\/div>\r\n        <\/div>\r\n        \t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t\t<div class=\"elementor-section elementor-top-section elementor-element elementor-element-fe34e6e elementor-section-boxed elementor-section-height-default elementor-section-height-default cms-remove-row-no cms-section-no-padding-no cms-boxed-bg-false cms-section-boxed-divider-false cms-overlay-gradient-bg-yes cms-overlay-gradient-mode-tb\" data-id=\"fe34e6e\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t<div class=\"cms-overlay-gradient\"><\/div><div class=\"cms-section-boxed-bg\"><\/div><div class=\"cms-section-boxed-divider\"><\/div><div class=\"cms-elementor-section-remove\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-top\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-bottom\"><\/div>\t\t\t<div class=\"elementor-container elementor-column-gap-default \" >\r\n\t\t\t        <div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5803eb2\" data-id=\"5803eb2\" data-element_type=\"column\" data-e-type=\"column\">\r\n            <div class=\"elementor-widget-wrap elementor-element-populated\">\r\n                \t\t<div class=\"elementor-element elementor-element-dc180f3 elementor-widget elementor-widget-heading\" data-id=\"dc180f3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">CASE STUDIES<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t            <\/div>\r\n        <\/div>\r\n        \t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t\t<div class=\"elementor-section elementor-top-section elementor-element elementor-element-4a0c75d elementor-section-boxed elementor-section-height-default elementor-section-height-default cms-remove-row-no cms-section-no-padding-no cms-boxed-bg-false cms-section-boxed-divider-false cms-overlay-gradient-bg-yes cms-overlay-gradient-mode-tb\" data-id=\"4a0c75d\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t<div class=\"cms-overlay-gradient\"><\/div><div class=\"cms-section-boxed-bg\"><\/div><div class=\"cms-section-boxed-divider\"><\/div><div class=\"cms-elementor-section-remove\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-top\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-bottom\"><\/div>\t\t\t<div class=\"elementor-container elementor-column-gap-default \" >\r\n\t\t\t        <div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-71f52b8\" data-id=\"71f52b8\" data-element_type=\"column\" data-e-type=\"column\">\r\n            <div class=\"elementor-widget-wrap elementor-element-populated\">\r\n                \t\t<div class=\"elementor-element elementor-element-e09664c elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"e09664c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t            <\/div>\r\n        <\/div>\r\n        \t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t\t<div class=\"elementor-section elementor-top-section elementor-element elementor-element-6ddb6af elementor-section-boxed elementor-section-height-default elementor-section-height-default cms-remove-row-no cms-section-no-padding-no cms-boxed-bg-false cms-section-boxed-divider-false cms-overlay-gradient-bg-yes cms-overlay-gradient-mode-tb\" data-id=\"6ddb6af\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t<div class=\"cms-overlay-gradient\"><\/div><div class=\"cms-section-boxed-bg\"><\/div><div class=\"cms-section-boxed-divider\"><\/div><div class=\"cms-elementor-section-remove\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-top\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-bottom\"><\/div>\t\t\t<div class=\"elementor-container elementor-column-gap-default \" >\r\n\t\t\t        <div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-961e0e1\" data-id=\"961e0e1\" data-element_type=\"column\" data-e-type=\"column\">\r\n            <div class=\"elementor-widget-wrap elementor-element-populated\">\r\n                \t\t<div class=\"elementor-element elementor-element-313a82a elementor-widget elementor-widget-text-editor\" data-id=\"313a82a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Let Vantage BioTrials\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. \u00a0All of our case-studies are real life situations which\u00a0can serve as valuable examples in creating\u00a0training tools for your needs.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t            <\/div>\r\n        <\/div>\r\n                <div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-a6b7cef\" data-id=\"a6b7cef\" data-element_type=\"column\" data-e-type=\"column\">\r\n            <div class=\"elementor-widget-wrap\">\r\n                            <\/div>\r\n        <\/div>\r\n        \t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t\t<div class=\"elementor-section elementor-top-section elementor-element elementor-element-d89efe8 elementor-section-boxed elementor-section-height-default elementor-section-height-default cms-remove-row-no cms-section-no-padding-no cms-boxed-bg-false cms-section-boxed-divider-false cms-overlay-gradient-bg-yes cms-overlay-gradient-mode-tb\" data-id=\"d89efe8\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t<div class=\"cms-overlay-gradient\"><\/div><div class=\"cms-section-boxed-bg\"><\/div><div class=\"cms-section-boxed-divider\"><\/div><div class=\"cms-elementor-section-remove\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-top\"><\/div><div class=\"cms-elementor-section-corner cms-elementor-section-corner-bottom\"><\/div>\t\t\t<div class=\"elementor-container elementor-column-gap-default \" >\r\n\t\t\t        <div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-76c8093\" data-id=\"76c8093\" data-element_type=\"column\" data-e-type=\"column\">\r\n            <div class=\"elementor-widget-wrap elementor-element-populated\">\r\n                \t\t<div class=\"elementor-element elementor-element-a7f3a07 elementor-widget elementor-widget-html\" data-id=\"a7f3a07\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-accordion .elementor-accordion-item:first-of-type {\ndisplay: none;}\n.elementor-accordion {\n  border-top: 1px solid  #D4DFF2C7;\n}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-46e9de9 elementor-widget elementor-widget-accordion\" data-id=\"46e9de9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-7431\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-7431\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Case Study 1: Competing Studies For a Phase III Infectious Disease Trial<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-7431\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-7431\"><p>VBT was aware of a number of ongoing studies in skin and skin structure infections, thus patient enrollment would potentially be affected by competing trials. Therefore, it was imperative that both our Sponsor and our internal team generate enthusiasm for this particular protocol. We began by enabling a comprehensive and targeted feasibility study to identify and evaluate upcoming competing studies, followed by an educative session with the Investigators on the biologic attributes of the study drug specifically with regard to its rapid bacteriacidal activity, potentially faster rates of resolution, and its potential to limit the development of resistance due to its multiple mechanisms of action. And finally, we recommended that the Sponsor offer more competitive Investigator grants. All these proactive steps resulted in targeted high enrollment rates for the majority of participating research sites.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-7432\" class=\"elementor-tab-title\" data-tab=\"2\" role=\"button\" aria-controls=\"elementor-tab-content-7432\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Case Study 1: Competing Studies For a Phase III Infectious Disease Trial<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-7432\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"region\" aria-labelledby=\"elementor-tab-title-7432\"><p><span style=\"font-weight: bold; outline: none !important;\"><span style=\"font-size: 24pt; line-height: 35.84px; font-family: Lato, sans-serif; color: #006e9f; outline: none !important;\">Executive Snapshot<\/span><\/span><\/p><p>A sponsor conducting a Phase III infectious disease trial faced significant enrollment pressure from multiple competing studies targeting the same patient population.<\/p><p>Rather than responding by replacing sites or opening additional locations, Vantage BioTrials (VBT) developed a targeted enrollment-risk strategy combining competitive intelligence, site-specific intervention planning, investigator engagement and optimized site support.<\/p><p><strong>Result:<\/strong> 85% of participating sites met or exceeded their enrollment targets and no site was withdrawn because of poor recruitment performance.<\/p><p><span style=\"color: #006e9f; font-family: Lato, sans-serif; font-size: 32px; font-weight: bold;\">The Challenge<\/span><\/p><p>The study was being conducted in a highly competitive clinical research environment involving several concurrent trials for skin and skin structure infections. Participating sites were competing for a limited pool of eligible patients while investigators had multiple protocols from which to choose.<\/p><p>This created three interrelated risks for the sponsor:<\/p><ul><li>Slower-than-planned enrollment and potential pressure on critical study milestones<\/li><li>Reduced investigator attention and site commitment<\/li><li>Additional costs associated with replacement sites, extended timelines or corrective recruitment initiatives<\/li><\/ul><p>The sponsor needed more than conventional site activation and follow-up. It required a strategy that could identify where enrollment pressure was most likely to occur and address the underlying causes before site performance deteriorated.<\/p><p><span style=\"color: #006e9f; font-family: Lato, sans-serif; font-size: 32px; font-weight: bold;\">Vantage BioTrials&#8217; Tailored Solutions<\/span><\/p><p>Vantage BioTrials worked with the sponsor to introduce a targeted enrollment-performance model based on four coordinated interventions.<\/p><ol><li><strong> Competitive-trial and enrollment-risk mapping<\/strong><\/li><\/ol><p>Vantage BioTrials assessed active and upcoming competing studies within the indication and evaluated their potential effect on individual sites and geographic markets.<\/p><p>The assessment considered factors such as competing protocol availability, target patient overlap, investigator interest, expected enrollment capacity and the relative operational burden of the sponsor\u2019s study. This produced a more realistic enrollment forecast and allowed higher-risk sites to be identified before recruitment performance declined.<\/p><ol start=\"2\"><li><strong> Site-specific engagement planning<\/strong><\/li><\/ol><p>Rather than applying the same recruitment strategy across every site, Vantage BioTrials helped prioritize interventions based on each site\u2019s circumstances, capabilities and competitive environment.<\/p><p>Sites received focused support based on emerging performance indicators, allowing the sponsor and Vantage BioTrials to direct attention where it could have the greatest effect.<\/p><ol start=\"3\"><li><strong> Investigator-focused scientific positioning<\/strong><\/li><\/ol><p>Vantage BioTrials collaborated with the sponsor to develop targeted educational sessions that clearly communicated the investigational product\u2019s scientific and potential clinical differentiation, including:<\/p><ul><li>Rapid bactericidal activity<\/li><li>Potential for faster clinical resolution<\/li><li>Multiple mechanisms of action intended to help limit the development of antimicrobial resistance<\/li><\/ul><p>The objective was not simply to repeat protocol training. It was to provide investigators with a compelling scientific rationale for prioritizing the study when several competing trials were available.<\/p><ol start=\"4\"><li><strong> More competitive site support<\/strong><\/li><\/ol><p>Vantage BioTrials reviewed the investigator-grant structure and recommended adjustments to better reflect the work required of sites and the competitive recruitment environment.<\/p><p>This helped remove a potential barrier to participation while reinforcing the sponsor\u2019s commitment to a productive, long-term relationship with its investigators.<\/p><p><span style=\"color: #006e9f; font-family: Lato, sans-serif; font-size: 32px; font-weight: bold;\">Results<\/span><\/p><p>The integrated strategy strengthened investigator engagement, stabilized site performance and maintained enrollment momentum in a highly competitive environment.<\/p><ul><li><strong>85% of participating sites met or exceeded their enrollment targets<\/strong><\/li><li><strong>No sites were withdrawn because of poor enrollment performance<\/strong><\/li><li>Enrollment velocity among targeted at-risk sites improved by an estimated <strong>20% within three months<\/strong> of implementing the intervention strategy<\/li><li>The sponsor avoided activating an estimated <strong>two to three replacement sites<\/strong>, preventing additional start-up costs and operational disruption<\/li><li>The study remained within approximately <strong>four weeks of its planned enrollment-completion milestone<\/strong>, despite the intensity of competing trials<\/li><li>Avoided site replacement and extended study-management activities represented an estimated <strong>US$250,000 in protected costs<\/strong><\/li><li>Site-specific enrollment interventions were developed and initiated within an average of <strong>10 business days<\/strong> after a performance risk was identified<\/li><\/ul><p>By improving the performance of the existing site network, Vantage BioTrials helped the sponsor preserve investigator relationships, avoid unnecessary site expansion and protect critical development timelines.<\/p><p><span style=\"color: #006e9f; font-family: Lato, sans-serif; font-size: 32px; font-weight: bold;\">Why This Matters to Sponsors<\/span><\/p><p>Enrollment challenges are rarely solved by increasing the frequency of status meetings or adding more sites after performance begins to decline. They require early risk detection, direct access to experienced decision-makers and the flexibility to design interventions around the realities of each study.<\/p><p>As a specialized CRO, Vantage BioTrials combines senior-level involvement with tailored, data-informed solutions. This enables sponsors to identify execution risks earlier, make decisions more quickly and avoid the layers of escalation that can delay corrective action within conventional outsourcing models.<\/p><p>The same approach can be applied across a sponsor\u2019s clinical development portfolio to strengthen site selection, enrollment planning, operational governance and inspection readiness from one program to the next.<\/p><p><span style=\"color: #006e9f; font-family: Lato, sans-serif; font-size: 32px; font-weight: bold;\">Key Takeaway<\/span><\/p><p>A CRO should do more than report that enrollment is behind plan. It should identify why performance is changing, determine where intervention will have the greatest impact and implement a practical strategy before the delay affects critical development milestones.<\/p><p>Vantage BioTrials helps sponsors translate clinical strategy into disciplined execution through proactive risk management, senior-level oversight and solutions designed around the needs of each program.<\/p><h4><strong>Planning an upcoming clinical program or facing enrollment pressure?<\/strong><\/h4><p><a title=\"Contact\" href=\"https:\/\/vantagebiotrials.com\/contact\/\" target=\"_blank\" rel=\"noopener\">Contact Vantage BioTrials about building enrollment resilience into your study strategy.<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-7433\" class=\"elementor-tab-title\" data-tab=\"3\" role=\"button\" aria-controls=\"elementor-tab-content-7433\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Case Study 2: Protecting Phase III Data Integrity<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-7433\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"region\" aria-labelledby=\"elementor-tab-title-7433\"><p><b><span style=\"font-size: 24.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%; font-family: 'Lato',sans-serif; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: #006e9f; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Protecting Phase III Data Integrity<\/span><\/b><\/p><h2 style=\"margin-bottom: 9.0pt; page-break-after: avoid;\"><span style=\"font-size: 13.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%;\">How an\u00a0early operational risk assessment prevented unintentional unblinding<\/span><\/h2><div align=\"center\"><table style=\"border-collapse: collapse; border: medium none currentcolor;\" border=\"1\" width=\"678\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr><td style=\"width: 508.3pt; border-width: medium; background: #eaf4f8; padding: 6.25pt 8.25pt;\" valign=\"top\" width=\"678\"><p style=\"margin-bottom: 0in;\"><b>Vantage BioTrials identified a hidden threat to the study blind before site activation and translated a complex protocol requirement into a practical, site-specific operating model, without disrupting enrollment or compromising data integrity.<\/b><\/p><\/td><\/tr><\/tbody><\/table><\/div><h1><span style=\"color: #7a7a7a; font-family: Roboto, sans-serif; font-size: 15px; outline: none !important;\"><span style=\"font-size: 24pt; line-height: 35.84px; font-family: Lato, sans-serif; color: #006e9f; outline: none !important;\">Study at a Glance<\/span><\/span><\/h1><div align=\"center\"><table style=\"border-collapse: collapse; border: medium none currentcolor;\" border=\"1\" width=\"678\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr><td style=\"width: 169.4pt; background: #f4f7f9; padding: 5.75pt 7pt; border: medium none currentcolor;\" width=\"226\"><p style=\"margin-bottom: 3.0pt; text-align: center;\" align=\"center\"><b><span style=\"font-size: 9.0pt; line-height: 112%; color: #006e9f;\">TRIAL<\/span><\/b><\/p><p style=\"margin-bottom: 0in; text-align: center; line-height: 102%;\" align=\"center\"><b><span style=\"font-size: 9.0pt; line-height: 102%;\">Phase III gastrointestinal study<\/span><\/b><\/p><\/td><td style=\"width: 169.45pt; background: #f4f7f9; padding: 5.75pt 7pt; border: medium none currentcolor;\" width=\"226\"><p style=\"margin-bottom: 3.0pt; text-align: center;\" align=\"center\"><b><span style=\"font-size: 9.0pt; line-height: 112%; color: #006e9f;\">CRITICAL RISK<\/span><\/b><\/p><p style=\"margin-bottom: 0in; text-align: center; line-height: 102%;\" align=\"center\"><b><span style=\"font-size: 9.0pt; line-height: 102%;\">Inadvertent disclosure of treatment allocation or drug-level data<\/span><\/b><\/p><\/td><td style=\"width: 169.45pt; border-width: medium; background: #f4f7f9; padding: 5.75pt 7pt;\" width=\"226\"><p style=\"margin-bottom: 3.0pt; text-align: center;\" align=\"center\"><b><span style=\"font-size: 9.0pt; line-height: 112%; color: #006e9f;\">VANTAGE BIOTRIALS INTERVENTION<\/span><\/b><\/p><p style=\"margin-bottom: 0in; text-align: center; line-height: 102%;\" align=\"center\"><b><span style=\"font-size: 9.0pt; line-height: 102%;\">Customized blinded\/unblinded operating model implemented before enrollment<\/span><\/b><\/p><\/td><\/tr><\/tbody><\/table><\/div><div><p><b style=\"color: #00277a; font-size: 36px;\"><span style=\"font-size: 24.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%; font-family: 'Lato',sans-serif; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: #006e9f; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">The Challenge<\/span><\/b><\/p><\/div><p>During an early operational review of a Phase III gastrointestinal trial, Vantage BioTrials identified a potentially study-critical vulnerability. The investigational product and comparator could not be fully blinded and therapeutic drug monitoring requirements differed across participating institutions.<\/p><p>At several sites, pharmacists or treating physicians were required to review drug concentration results as part of routine patient management. Without a clearly separated operating model, treatment allocation or concentration data could inadvertently reach blinded investigators, study coordinators or outcome assessors.<\/p><p>An unblinding event at even one high-enrolling site could introduce bias, trigger protocol deviations, require retrospective data-impact assessments and raise questions about the reliability of efficacy or safety results. The protocol established the requirement to preserve the blind but did not fully address how each institution could achieve this within its existing workflows.<\/p><h1><b><span style=\"font-size: 24.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%; font-family: 'Lato',sans-serif; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: #006e9f; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Vantage BioTrials&#8217; Strategic Insight<\/span><\/b><\/h1><p>Vantage BioTrials recognized that a standardized study-wide instruction would not adequately control the risk. Each institution had different pharmacy structures, laboratory reporting processes, electronic access permissions and clinical communication pathways.<\/p><p>Rather than force every site into a rigid process, Vantage BioTrials established a common control framework that could be adapted locally while maintaining consistent study-wide safeguards. The solution drew on lessons from a previously completed study with similar design characteristics and was implemented before site activation and patient enrollment.<\/p><p><b><span style=\"font-size: 24.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%; font-family: 'Lato',sans-serif; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: #006e9f; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">The Vantage BioTrials Solution<\/span><\/b><\/p><h2>From protocol requirement to executable site controls<\/h2><div align=\"center\"><table style=\"border-collapse: collapse; border: medium none currentcolor;\" border=\"1\" width=\"678\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr><td style=\"width: 254.15pt; background: #eaf4f8; padding: 6pt 7.25pt 5.5pt; border: medium none currentcolor;\" valign=\"top\" width=\"339\"><p style=\"margin-bottom: 4.0pt;\"><b><span style=\"color: #006e9f;\">1\u00a0 Risk and workflow mapping<\/span><\/b><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Mapped every point where treatment allocation or concentration data could become visible.<\/span><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Assessed pharmacy, laboratory, electronic access and communication workflows.<\/span><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Defined which roles required unblinded access and which had to remain protected.<\/span><\/p><\/td><td style=\"width: 254.15pt; background: #f4f7f9; padding: 6pt 7.25pt 5.5pt; border: medium none currentcolor;\" valign=\"top\" width=\"339\"><p style=\"margin-bottom: 4.0pt;\"><b><span style=\"color: #006e9f;\">2\u00a0 Customized operating model<\/span><\/b><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Created site-specific blinding plans aligned with institutional requirements.<\/span><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Established separate blinded and unblinded roles, access controls and communication pathways.<\/span><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Defined escalation procedures for potential or emergency unblinding situations.<\/span><\/p><\/td><\/tr><tr><td style=\"width: 254.15pt; background: #f4f7f9; padding: 6pt 7.25pt 5.5pt; border: medium none currentcolor;\" valign=\"top\" width=\"339\"><p style=\"margin-bottom: 4.0pt;\"><b><span style=\"color: #006e9f;\">3\u00a0 Pre-enrollment implementation<\/span><\/b><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Assigned dedicated unblinded monitors for activities capable of revealing treatment allocation.<\/span><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Trained relevant site and monitoring personnel before enrollment.<\/span><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Verified that every participating center had functional controls in place before enrolling participants.<\/span><\/p><\/td><td style=\"width: 254.15pt; border-width: medium; background: #eaf4f8; padding: 6pt 7.25pt 5.5pt;\" valign=\"top\" width=\"339\"><p style=\"margin-bottom: 4.0pt;\"><b><span style=\"color: #006e9f;\">4\u00a0 Ongoing oversight<\/span><\/b><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Monitored drug dispensing, dosing, storage and accountability.<\/span><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Reviewed therapeutic drug monitoring processes for continued separation.<\/span><\/p><p style=\"mso-add-space: auto; text-indent: -9.35pt; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in; margin: 0in 0in 2.0pt 11.5pt;\"><!-- [if !supportLists]--><span style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0 <\/span><\/span><!--[endif]--><span style=\"font-size: 8.5pt; mso-bidi-font-size: 11.0pt;\">Reconciled used and unused supplies and maintained traceable, inspection-ready documentation.<\/span><\/p><\/td><\/tr><\/tbody><\/table><\/div><h2>Measurable outcomes<\/h2><div align=\"center\"><table style=\"border-collapse: collapse; border: medium none currentcolor;\" border=\"1\" width=\"678\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr><td style=\"width: 127.05pt; background: #006e9f; padding: 5.25pt; border: medium none currentcolor;\" width=\"169\"><p style=\"margin-bottom: 1.0pt; text-align: center;\" align=\"center\"><b><span style=\"font-size: 17.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%; color: white;\">0<\/span><\/b><\/p><p style=\"margin-bottom: 0in; text-align: center; line-height: normal;\" align=\"center\"><span style=\"font-size: 7.5pt; mso-bidi-font-size: 11.0pt; color: white;\">documented unblinding events<\/span><\/p><\/td><td style=\"width: 127.05pt; background: #006e9f; padding: 5.25pt; border: medium none currentcolor;\" width=\"169\"><p style=\"margin-bottom: 1.0pt; text-align: center;\" align=\"center\"><b><span style=\"font-size: 17.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%; color: white;\">0<\/span><\/b><\/p><p style=\"margin-bottom: 0in; text-align: center; line-height: normal;\" align=\"center\"><span style=\"font-size: 7.5pt; mso-bidi-font-size: 11.0pt; color: white;\">blinding-related protocol deviations<\/span><\/p><\/td><td style=\"width: 127.1pt; background: #006e9f; padding: 5.25pt; border: medium none currentcolor;\" width=\"169\"><p style=\"margin-bottom: 1.0pt; text-align: center;\" align=\"center\"><b><span style=\"font-size: 17.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%; color: white;\">100%<\/span><\/b><\/p><p style=\"margin-bottom: 0in; text-align: center; line-height: normal;\" align=\"center\"><span style=\"font-size: 7.5pt; mso-bidi-font-size: 11.0pt; color: white;\">of centers had controls verified before enrollment<\/span><\/p><\/td><td style=\"width: 127.1pt; border-width: medium; background: #006e9f; padding: 5.25pt;\" width=\"169\"><p style=\"margin-bottom: 1.0pt; text-align: center;\" align=\"center\"><b><span style=\"font-size: 17.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%; color: white;\">100%<\/span><\/b><\/p><p style=\"margin-bottom: 0in; text-align: center; line-height: normal;\" align=\"center\"><span style=\"font-size: 7.5pt; mso-bidi-font-size: 11.0pt; color: white;\">of drug accountability records reconciled without compromising the blind<\/span><\/p><\/td><\/tr><\/tbody><\/table><\/div><p><span style=\"font-size: 10.0pt; mso-bidi-font-size: 11.0pt; line-height: 112%; font-family: 'Lato',sans-serif; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: #243746; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">The strategy allowed sites to meet therapeutic drug monitoring requirements while maintaining a clear separation between blinded and unblinded activities. By resolving the vulnerability before enrollment, the sponsor avoided the need for reactive remediation, retrospective impact assessments and potential questions regarding the usability of affected participant data.<\/span><\/p><h1><span style=\"color: #7a7a7a; font-family: Roboto, sans-serif; font-size: 15px; outline: none !important;\"><span style=\"font-size: 24pt; line-height: 35.84px; font-family: Lato, sans-serif; color: #006e9f; outline: none !important;\">Why This Matters to Sponsors<\/span><\/span><\/h1><p class=\"MsoNormal\" style=\"margin-bottom: 3.0pt;\">Lean biotech teams depend on their CRO to identify risks that are not fully resolved by protocol language. VBT does not wait for an issue to become a deviation before addressing it. By bringing senior clinical operations and quality expertise into study planning, VBT helps sponsors translate complex protocols into practical operating models that sites can execute consistently.<\/p><div align=\"center\"><table class=\"MsoNormalTable\" style=\"border-collapse: collapse; border: medium none currentcolor;\" border=\"1\" width=\"678\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr><td style=\"width: 508.3pt; border-width: medium; background: #eaf4f8; padding: 5.75pt 8pt;\" width=\"678\"><p class=\"MsoNormal\" style=\"margin-bottom: 3.0pt; text-align: center;\" align=\"center\"><b><span style=\"mso-bidi-font-size: 14.0pt; line-height: 112%; color: #006e9f;\">YOUR\u00a0 ADVANTAGE<\/span><\/b><\/p><p class=\"MsoNormal\" style=\"margin-bottom: 0in; text-align: center; line-height: 105%;\" align=\"center\"><b>Senior-level involvement \u2022 Customized solutions \u2022 Quality by Design integrated into clinical operations \u2022 Controls adapted to real site workflows \u2022 Early intervention before risks affect patients, timelines or data<\/b><\/p><\/td><\/tr><\/tbody><\/table><\/div><p><strong>Is your protocol operationally executable at every site?<\/strong><\/p><p><a href=\"https:\/\/vantagebiotrials.com\/contact\/\" target=\"_blank\" rel=\"noopener\">Contact Vantage BioTrials about your upcoming clinical program.<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-7434\" class=\"elementor-tab-title\" data-tab=\"4\" role=\"button\" aria-controls=\"elementor-tab-content-7434\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Case Study 3: How Patient-Journey Mapping Protected Eligibility in a Phase II Acute Variceal Bleeding Trial<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-7434\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"4\" role=\"region\" aria-labelledby=\"elementor-tab-title-7434\"><h2 style=\"line-height: normal;\"><b><span style=\"font-size: 17.0pt; font-family: 'Lato Light',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">The Challenge<\/span><\/b><\/h2><p>A biotechnology sponsor conducting a Phase II trial in\u00a0patients with acute variceal bleeding faced a significant enrollment and evaluability risk.<\/p><p>Because patients required urgent medical intervention,\u00a0potentially eligible participants frequently entered the hospital through emergency departments or other acute-care units. By the time the research team was notified, medically necessary non-study therapies may already have been administered, making the patient ineligible under the protocol.<\/p><p><span style=\"font-size: 12.0pt; line-height: 115%; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">The underlying risk was therefore not limited to recruitment performance. It existed within the patient\u2019s journey through the hospital, before the individual reached the research team.<\/span><\/p><h2 style=\"line-height: normal;\"><span style=\"font-size: 18.0pt; font-family: 'Lato',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">The Operational Insight<\/span><\/h2><p>Vantage BioTrials mapped how potential participants moved through emergency medicine, gastroenterology, hepatology, critical care, and research services.<\/p><p>This assessment identified the critical failure point: the interval between initial presentation, clinical assessment, treatment decisions, and notification of study personnel.<\/p><p><span style=\"font-size: 12.0pt; line-height: 115%; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Rather than relying solely on conventional site\u00a0recruitment tactics, VBT developed a cross-department strategy designed to enable earlier identification and rapid research-team notification where\u00a0clinically appropriate, without delaying or interfering with necessary patient care.<\/span><\/p><h2 style=\"line-height: normal;\"><span style=\"font-size: 20.0pt; font-family: 'Lato Medium',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">The Vantage BioTrials Approach<\/span><\/h2><p>Vantage BioTrials implemented four integrated operational controls:<\/p><p style=\"margin-left: .5in;\"><b>Strategic site selection<\/b><br \/>Sites were evaluated not only on access to eligible patients but also on their\u00a0ability to coordinate care and communicate across the clinical departments\u00a0involved in the patient pathway.<\/p><p style=\"margin-left: .5in;\"><b>Cross-department training<\/b><br \/>Training extended beyond investigators and study coordinators to emergency department personnel and other frontline healthcare professionals involved in\u00a0initial patient assessment and treatment.<\/p><p style=\"margin-left: .5in;\"><b>Site-specific referral pathways<\/b><br \/>Each site developed a customized plan defining patient-identification procedures, escalation pathways, departmental responsibilities, and rapid\u00a0notification processes.<\/p><p style=\"margin-left: .5in;\"><b>Point-of-care eligibility tools<\/b><br \/>Concise reference cards summarized critical eligibility criteria and provided direct contact information for study coordinators and investigators. These\u00a0tools were distributed across relevant departments to support timely identification and referral.<\/p><p><span style=\"font-size: 12.0pt; line-height: 115%; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">All training and site-specific referral plans\u00a0were completed before the applicable sites began enrollment.<\/span><\/p><h2 style=\"line-height: normal;\"><b><span style=\"font-size: 22.0pt; font-family: 'Lato Medium',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">The Outcome<\/span><\/b><\/h2><ul><li><span style=\"font-weight: normal;\"><span style=\"color: #7a7a7a; font-family: Roboto, sans-serif; font-size: 15px;\">100%\u00a0of participating sites<\/span><span style=\"color: #7a7a7a; font-family: Roboto, sans-serif; font-size: 15px;\"> completed eligibility and referral-pathway training before activation.<\/span><\/span><\/li><li><span style=\"font-weight: normal;\"><span style=\"color: #7a7a7a; font-family: Roboto, sans-serif; font-size: 15px;\">100%\u00a0of participating sites<\/span><span style=\"color: #7a7a7a; font-family: Roboto, sans-serif; font-size: 15px;\"> implemented site-specific referral plans before enrolling their first patient.<\/span><\/span><\/li><li><span style=\"font-weight: normal;\"><span style=\"color: #7a7a7a; font-family: Roboto, sans-serif; font-size: 15px;\">Zero major protocol deviations<\/span><span style=\"color: #7a7a7a; font-family: Roboto, sans-serif; font-size: 15px;\"> related to eligibility or administration of protocol-disqualifying therapies were reported during study conduct.<\/span><\/span><\/li><\/ul><p><span style=\"font-size: 12.0pt; line-height: 115%; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">The\u00a0approach established consistent operational controls across participating institutions, reduced preventable eligibility risks, and protected patient\u00a0evaluability.<\/span><\/p><h2 style=\"font-family: Lexend, sans-serif; font-weight: 600; color: #00277a; line-height: normal; outline: none !important;\"><span style=\"outline: none !important;\"><span style=\"color: #0070c0; font-size: 22pt; font-family: 'Lato Medium', sans-serif; outline: none !important;\">The Vantage BioTrials AdVantage<\/span><\/span><\/h2><p>Complex enrollment problems are not always solved by adding\u00a0sites or increasing recruitment spending. In acute-care studies, the decisive risk may occur before the research team even knows that a potential participant has arrived.<\/p><p>Vantage BioTrials applies Quality by Design to real-world\u00a0patient pathways, identifying execution risks early and implementing practical, site-specific solutions that protect eligibility, data quality, and study\u00a0timelines.<\/p><p><b>Facing a clinical trial challenge that conventional approaches have not solved?\u00a0<\/b><\/p><p><a href=\"https:\/\/vantagebiotrials.com\/contact\/\" target=\"_blank\" rel=\"noopener\">Contact Vantage BioTrials about your study.<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-7435\" class=\"elementor-tab-title\" data-tab=\"5\" role=\"button\" aria-controls=\"elementor-tab-content-7435\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Case Study 4: Strengthening Manufacturing and Imaging Continuity in a Radiopharmaceutical Clinical Trial<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-7435\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"5\" role=\"region\" aria-labelledby=\"elementor-tab-title-7435\"><p><b><span style=\"font-size: 17.0pt; line-height: 115%; font-family: 'Lato Light',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">At a Glance <\/span><\/b><\/p><p><b><span style=\"font-family: 'Lato',sans-serif;\">Operational risk<\/span><\/b><span style=\"font-family: 'Lato',sans-serif;\">: Dependence on a single investigational product manufacturing source, combined with limited\u00a0imaging availability, threatened participant retention, enrollment, and study timelines.<\/span><\/p><p><b><span style=\"font-family: 'Lato',sans-serif;\">Intervention<\/span><\/b><span style=\"font-family: 'Lato',sans-serif;\">: Vantage BioTrials anticipated the supply risk during study planning, escalated it when batch-release failures occurred, and led an integrated mitigation strategy involving second-source qualification, imaging-capacity assessment, participant-scheduling controls, and enhanced operational governance.<\/span><\/p><p><b><span style=\"font-family: 'Lato',sans-serif;\">Sponsor benefit<\/span><\/b><span style=\"font-family: 'Lato',sans-serif;\">: An additional manufacturing source was qualified and activated within approximately 7 weeks, increasing production flexibility, reducing single-source dependency, and allowing the study to continue without a prolonged enrollment suspension.<\/span><\/p><p><span style=\"font-size: 18.0pt; line-height: 115%; font-family: 'Lato',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">The Challenge: A Critical Dependency Identified Before It Disrupted the Study<\/span><\/p><p>During the planning of a radiopharmaceutical clinical trial conducted at two specialized imaging sites, Vantage BioTrials identified investigational product manufacturing capacity and availability as material risks to study execution.<\/p><p>The initial operating model relied primarily on a single manufacturing source. Because the investigational product had to be manufactured, quality-control tested, released, administered, and imaged within tightly coordinated timeframes, a disruption at any point in that pathway could result in a cancelled participant visit.<\/p><p>Vantage BioTrials documented the single-source dependency during study planning and recommended that contingency manufacturing capacity be evaluated. At study initiation, however, the Sponsor assessed the likelihood of a significant supply interruption as low, and the study proceeded under the original manufacturing model.<\/p><p>The risk subsequently materialized.<\/p><p>During study conduct, investigational product could not be released on four separate occasions at one participating site because the manufactured batches did not meet applicable release requirements or could not be released within the required operational window. These events resulted in 3 participant withdrawals, the rescheduling of 4 participant visits, delayed imaging procedures, additional site burden, and increasing pressure on the enrollment timeline.<\/p><p>The manufacturing interruptions also exposed a second operational constraint: imaging capacity.<\/p><p>Although investigational product production was available weekly, scanner access was limited to narrow, site-specific scheduling windows. Participant availability, manufacturing slots, quality-control release, product administration, and imaging capacity therefore had to align on the same day. The study did not simply have a manufacturing problem, it had an interconnected capacity-management problem spanning several operational functions.<\/p><p><span style=\"color: #0070c0; font-family: 'Lato Medium', sans-serif; font-size: 20pt;\">Vantage BioTrials\u2019 Response: Moving from Event Management to Controlled Risk Mitigation<\/span><\/p><p>Rather than managing each failed release as an isolated scheduling issue, Vantage BioTrials escalated the recurring events as a systemic risk to study continuity.<\/p><p><span style=\"font-family: Lato, sans-serif;\">Vantage BioTrials led a cross-functional impact assessment involving the Sponsor, manufacturing and quality representatives, nuclear medicine personnel, imaging teams, and participating sites. <\/span><\/p><p><span style=\"font-family: Lato, sans-serif;\">The assessment examined:<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/span><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">The causes and operational consequences of the four release interruptions;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0 <\/span><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">The study\u2019s dependency on the primary manufacturing source;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0 <\/span><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">The relationship among manufacturing, quality-control release, participant dosing, and imaging windows;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0 <\/span><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Available production and imaging capacity at both participating sites;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0 <\/span><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Participant eligibility and protocol-window implications;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0 <\/span><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">The likelihood and potential impact of additional disruptions; and<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0 <\/span><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">The feasibility of establishing an alternative manufacturing pathway.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">The assessment\u00a0confirmed that continued dependence on a single manufacturing source created an unacceptable residual risk to participant retention and study timelines. Vantage\u00a0BioTrials recommended activation of a second manufacturing facility located at the other participating site and presented the Sponsor with a controlled mitigation plan.<\/span><\/p><h2 style=\"line-height: normal;\"><b><span style=\"font-size: 22.0pt; font-family: 'Lato Medium',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">Establishing an Additional Manufacturing Source<\/span><\/b><\/h2><p><span style=\"font-family: 'Lato',sans-serif;\">Vantage BioTrials coordinated the operational workstream required to qualify and\u00a0integrate the second facility into the study. Activities included, as<br \/>applicable:<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l2 level1 lfo3;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Defining\u00a0facility-readiness and study-specific qualification requirements;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l2 level1 lfo3;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Coordinating the collection and review of manufacturing, quality, and release documentation;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l2 level1 lfo3;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Assessing\u00a0site infrastructure, production capacity, and quality-control capabilities;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l2 level1 lfo3;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Evaluating the regulatory and study-document implications of the proposed change;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l2 level1 lfo3;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Supporting\u00a0quality-agreement and responsibility-alignment activities;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l2 level1 lfo3;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Coordinating\u00a0updates to applicable study plans, manuals, instructions, and training;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l2 level1 lfo3;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Confirming\u00a0readiness across manufacturing, pharmacy, radiation-safety, clinical, and imaging personnel; and<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l2 level1 lfo3;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Tracking activation activities, dependencies, owners, and escalation points through\u00a0completion.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">The second\u00a0manufacturing facility was qualified and operationally integrated within approximately 7 weeks of Sponsor authorization.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">This created an alternative production pathway, reduced dependence on the original facility, and provided greater flexibility in assigning participants to available manufacturing and imaging windows.<\/span><\/p><h2 style=\"line-height: normal;\"><b><span style=\"font-size: 22.0pt; font-family: 'Lato Medium',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">Integrating Imaging Capacity into Operational Planning<\/span><\/b><\/h2><p><span style=\"font-family: 'Lato',sans-serif;\">Vantage BioTrials also determined that adding manufacturing capacity alone would not resolve the underlying execution risk. Scanner availability had to be managed as part of the same operational pathway.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">Vantage BioTrials completed site-specific capacity assessments that mapped:<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l1 level1 lfo5;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Weekly\u00a0manufacturing availability;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l1 level1 lfo5;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Quality-control\u00a0testing and anticipated release timing;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l1 level1 lfo5;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Product\u00a0administration requirements;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l1 level1 lfo5;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Scanner availability and protected imaging windows;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l1 level1 lfo5;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Participant travel and scheduling considerations;<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l1 level1 lfo5;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Protocol-defined visit windows; and<\/span><\/p><p style=\"margin-left: .75in; mso-add-space: auto; text-indent: -.5in; mso-list: l1 level1 lfo5;\"><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Site\u00a0staffing and departmental dependencies.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">Based on these assessments, Vantage BioTrials worked with the sites and Sponsor to implement a\u00a0more structured scheduling model. Manufacturing and imaging availability were reviewed together before participant appointments were finalized, and potential conflicts were escalated before production or participant travel occurred.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">The study team also established weekly capacity reviews, defined scheduling cut-off points,\u00a0and maintained contingency options for participants at risk of missing protocol-defined windows.<\/span><\/p><h2 style=\"line-height: normal;\"><b><span style=\"font-size: 22.0pt; font-family: 'Lato Medium',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">Results: Greater Resilience and Continued Study Execution<\/span><\/b><\/h2><p><span style=\"font-family: 'Lato',sans-serif;\">Vantage BioTrials\u2019 intervention converted a recurring operational disruption into a controlled continuity strategy.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">Following implementation:<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">A\u00a0second qualified manufacturing source became available to support study conduct;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Single-source manufacturing dependency was materially reduced;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Available production and scheduling flexibility increased by approximately 90%;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Manufacturing and scanner capacity were managed through an integrated planning process;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">No additional participant withdrawals attributable to single-source manufacturing dependency occurred during the remaining study period;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">The study continued without a prolonged enrollment suspension;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Potential\u00a0scheduling conflicts were identified earlier, before participant travel and\u00a0product production; and<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">The\u00a0Sponsor gained clearer visibility into capacity constraints, mitigation status, and residual operational risk.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">The intervention did not eliminate the inherent complexity of radiopharmaceutical manufacturing and imaging. Instead, it gave the Sponsor and study team the governance,\u00a0contingency capacity, and operational visibility required to manage that\u00a0complexity without allowing individual disruptions to evolve into a broader study failure.<\/span><\/p><h2 style=\"line-height: normal;\"><b><span style=\"font-size: 22.0pt; font-family: 'Lato Medium',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">Sponsor\u00a0Value: Anticipating Risk Before It Becomes a Timeline Failure<\/span><\/b><\/h2><p><span style=\"font-family: 'Lato',sans-serif;\">This case\u00a0illustrates why radiopharmaceutical trial readiness must be evaluated across the complete participant-treatment pathway.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">Manufacturing availability alone does not establish operational feasibility. Production, quality-control testing, batch release, product administration, participant availability, scanner access, specialized personnel, and protocol-defined imaging windows must function as one coordinated system.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">Vantage BioTrials identified the single-source dependency before it materialized, maintained visibility of the risk during study conduct, and acted decisively when the operating assumptions no longer remained acceptable. By combining structured escalation, cross-functional governance, second-source\u00a0qualification, and integrated capacity planning, Vantage BioTrials helped the Sponsor preserve study continuity and reduce the risk of further participant and timeline disruption.<\/span><\/p><h2 style=\"line-height: normal;\"><b><span style=\"font-size: 22.0pt; font-family: 'Lato Medium',sans-serif; color: #0070c0; mso-font-kerning: 0pt; mso-ligatures: none;\">Key\u00a0Takeaway<\/span><\/b><\/h2><p><span style=\"font-family: 'Lato',sans-serif;\">In radiopharmaceutical trials, a CRO must do more than track enrollment and respond to individual site issues. It must understand how manufacturing, quality release, imaging, and clinical operations interact, and recognize when\u00a0an isolated event signals a systemic risk.<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">Vantage\u00a0BioTrials applies Quality by Design and risk-based clinical oversight to:<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Identify fragile operational dependencies during planning;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Challenge assumptions that could place participants or timelines at risk;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Establish clear risk ownership and escalation thresholds;<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\">\u00a0 \u00a0 \u00a0 \u00a0 <\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Coordinate controlled, cross-functional mitigation strategies; and<\/span><\/p><p><span style=\"font-family: 'Lato',sans-serif;\"> \u00a0 \u00a0 \u00a0 \u00a0<\/span><!-- [if !supportLists]--><span style=\"font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;\">\u00a7<span style=\"font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0<\/span><\/span><span style=\"font-family: 'Lato',sans-serif;\">Maintain alignment among manufacturing, imaging, sites, and clinical operations throughout study conduct.<\/span><\/p><h4><b><span style=\"font-family: 'Lato',sans-serif;\">Planning a radiopharmaceutical study or experiencing manufacturing, imaging, or site-capacity constraints?<\/span><\/b><\/h4><p><a title=\"Contact\" href=\"https:\/\/vantagebiotrials.com\/contact\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-family: 'Lato',sans-serif;\">Contact Vantage BioTrials to assess your operational readiness and develop a risk-based clinical execution strategy.<\/span><\/a><\/p><p><span style=\"font-size: 12.0pt; line-height: 115%; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-no-proof: yes;\"><!-- [if gte vml 1]><v:shapetype id=\"_x0000_t75\" coordsize=\"21600,21600\" o:spt=\"75\" o:preferrelative=\"t\" path=\"m@4@5l@4@11@9@11@9@5xe\" filled=\"f\" stroked=\"f\"><br \/> <v:stroke joinstyle=\"miter\"\/><br \/> <v:formulas><br \/>  <v:f eqn=\"if lineDrawn pixelLineWidth 0\"\/><br \/>  <v:f eqn=\"sum @0 1 0\"\/><br \/>  <v:f eqn=\"sum 0 0 @1\"\/><br \/>  <v:f eqn=\"prod @2 1 2\"\/><br \/>  <v:f eqn=\"prod @3 21600 pixelWidth\"\/><br \/>  <v:f eqn=\"prod @3 21600 pixelHeight\"\/><br \/>  <v:f eqn=\"sum @0 0 1\"\/><br \/>  <v:f eqn=\"prod @6 1 2\"\/><br \/>  <v:f eqn=\"prod @7 21600 pixelWidth\"\/><br \/>  <v:f eqn=\"sum @8 21600 0\"\/><br \/>  <v:f eqn=\"prod @7 21600 pixelHeight\"\/><br \/>  <v:f eqn=\"sum @10 21600 0\"\/><br \/> <\/v:formulas><br \/> <v:path o:extrusionok=\"f\" gradientshapeok=\"t\" o:connecttype=\"rect\"\/><br \/> <o:lock v:ext=\"edit\" aspectratio=\"t\"\/><br \/><\/v:shapetype><v:shape id=\"Picture_x0020_2\" o:spid=\"_x0000_i1025\" type=\"#_x0000_t75\" style='width:468.4pt;height:263.65pt;visibility:visible;mso-wrap-style:square'><br \/> <v:imagedata src=\"file:\/\/\/C:\/Users\/vikenb\/AppData\/Local\/Temp\/msohtmlclip1\/01\/clip_image001.jpg\" o:title=\"\"\/><br \/><\/v:shape><![endif]--><!-- [if !vml]--><img decoding=\"async\" class=\"aligncenter\" src=\"data:image\/jpeg;base64,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\" width=\"625\" height=\"352\" \/><!--[endif]--><\/span><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t            <\/div>\r\n        <\/div>\r\n        \t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>CASE STUDIES Let Vantage BioTrials\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. \u00a0All of our case-studies are real life situations which\u00a0can serve as valuable examples in creating\u00a0training tools for your needs. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial VBT was aware of a number of ongoing studies in skin and skin structure infections, thus patient enrollment would potentially be affected by competing trials. Therefore, it was imperative that both our Sponsor and our internal team generate enthusiasm for this particular protocol. We began by enabling a comprehensive and targeted feasibility study to identify and evaluate upcoming competing studies, followed by an educative session with the Investigators on the biologic attributes of the study drug specifically with regard to its rapid bacteriacidal activity, potentially faster rates of resolution, and its potential to limit the development of resistance due to its multiple mechanisms of action. And finally, we recommended that the Sponsor offer more competitive Investigator grants. All these proactive steps resulted in targeted high enrollment rates for the majority of participating research sites. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial Executive Snapshot A sponsor conducting a Phase III infectious disease trial faced significant enrollment pressure from multiple competing studies targeting the same patient population. Rather than responding by replacing sites or opening additional locations, Vantage BioTrials (VBT) developed a targeted enrollment-risk strategy combining competitive intelligence, site-specific intervention planning, investigator engagement and optimized site support. Result: 85% of participating sites met or exceeded their enrollment targets and no site was withdrawn because of poor recruitment performance. The Challenge The study was being conducted in a highly competitive clinical research environment involving several concurrent trials for skin and skin structure infections. Participating sites were competing for a limited pool of eligible patients while investigators had multiple protocols from which to choose. This created three interrelated risks for the sponsor: Slower-than-planned enrollment and potential pressure on critical study milestones Reduced investigator attention and site commitment Additional costs associated with replacement sites, extended timelines or corrective recruitment initiatives The sponsor needed more than conventional site activation and follow-up. It required a strategy that could identify where enrollment pressure was most likely to occur and address the underlying causes before site performance deteriorated. Vantage BioTrials&#8217; Tailored Solutions Vantage BioTrials worked with the sponsor to introduce a targeted enrollment-performance model based on four coordinated interventions. Competitive-trial and enrollment-risk mapping Vantage BioTrials assessed active and upcoming competing studies within the indication and evaluated their potential effect on individual sites and geographic markets. The assessment considered factors such as competing protocol availability, target patient overlap, investigator interest, expected enrollment capacity and the relative operational burden of the sponsor\u2019s study. This produced a more realistic enrollment forecast and allowed higher-risk sites to be identified before recruitment performance declined. Site-specific engagement planning Rather than applying the same recruitment strategy across every site, Vantage BioTrials helped prioritize interventions based on each site\u2019s circumstances, capabilities and competitive environment. Sites received focused support based on emerging performance indicators, allowing the sponsor and Vantage BioTrials to direct attention where it could have the greatest effect. Investigator-focused scientific positioning Vantage BioTrials collaborated with the sponsor to develop targeted educational sessions that clearly communicated the investigational product\u2019s scientific and potential clinical differentiation, including: Rapid bactericidal activity Potential for faster clinical resolution Multiple mechanisms of action intended to help limit the development of antimicrobial resistance The objective was not simply to repeat protocol training. It was to provide investigators with a compelling scientific rationale for prioritizing the study when several competing trials were available. More competitive site support Vantage BioTrials reviewed the investigator-grant structure and recommended adjustments to better reflect the work required of sites and the competitive recruitment environment. This helped remove a potential barrier to participation while reinforcing the sponsor\u2019s commitment to a productive, long-term relationship with its investigators. Results The integrated strategy strengthened investigator engagement, stabilized site performance and maintained enrollment momentum in a highly competitive environment. 85% of participating sites met or exceeded their enrollment targets No sites were withdrawn because of poor enrollment performance Enrollment velocity among targeted at-risk sites improved by an estimated 20% within three months of implementing the intervention strategy The sponsor avoided activating an estimated two to three replacement sites, preventing additional start-up costs and operational disruption The study remained within approximately four weeks of its planned enrollment-completion milestone, despite the intensity of competing trials Avoided site replacement and extended study-management activities represented an estimated US$250,000 in protected costs Site-specific enrollment interventions were developed and initiated within an average of 10 business days after a performance risk was identified By improving the performance of the existing site network, Vantage BioTrials helped the sponsor preserve investigator relationships, avoid unnecessary site expansion and protect critical development timelines. Why This Matters to Sponsors Enrollment challenges are rarely solved by increasing the frequency of status meetings or adding more sites after performance begins to decline. They require early risk detection, direct access to experienced decision-makers and the flexibility to design interventions around the realities of each study. As a specialized CRO, Vantage BioTrials combines senior-level involvement with tailored, data-informed solutions. This enables sponsors to identify execution risks earlier, make decisions more quickly and avoid the layers of escalation that can delay corrective action within conventional outsourcing models. The same approach can be applied across a sponsor\u2019s clinical development portfolio to strengthen site selection, enrollment planning, operational governance and inspection readiness from one program to the next. Key Takeaway A CRO should do more than report that enrollment is behind plan. It should identify why performance is changing, determine where intervention will have the greatest impact and implement a practical strategy before the delay affects critical development milestones. Vantage BioTrials helps sponsors translate clinical strategy into disciplined execution through proactive risk management, senior-level oversight and solutions designed around the needs of each program. Planning an upcoming clinical program or facing enrollment pressure? Contact Vantage BioTrials about building enrollment resilience into your study strategy. Case Study 2: Protecting Phase III Data Integrity Protecting Phase III Data Integrity How an\u00a0early operational risk assessment prevented unintentional unblinding Vantage BioTrials identified a hidden threat to the study blind before site activation and translated a complex protocol requirement into a practical, site-specific operating model, without disrupting enrollment or compromising data integrity. Study at a Glance TRIAL Phase III gastrointestinal study CRITICAL RISK Inadvertent disclosure of treatment allocation or drug-level data VANTAGE BIOTRIALS INTERVENTION Customized blinded\/unblinded operating model implemented before enrollment The Challenge During an early operational review of a Phase III gastrointestinal trial, Vantage BioTrials identified a potentially study-critical vulnerability. The investigational product and comparator could not be fully blinded and therapeutic drug monitoring requirements differed across participating institutions. At several sites, pharmacists or treating physicians were required to review drug concentration results as part of routine patient management. Without a clearly separated operating model, treatment allocation or concentration data could inadvertently reach blinded investigators, study coordinators or outcome assessors. An unblinding event at even one high-enrolling site could introduce bias, trigger protocol deviations, require retrospective data-impact assessments and raise questions about the reliability of efficacy or safety results. The protocol established the requirement to preserve the blind but did not fully address how each institution could achieve this within its existing workflows. Vantage BioTrials&#8217; Strategic Insight Vantage BioTrials recognized that a standardized study-wide instruction would not adequately control the risk. Each institution had different pharmacy structures, laboratory reporting processes, electronic access permissions and clinical communication pathways. Rather than force every site into a rigid process, Vantage BioTrials established a common control framework that could be adapted locally while maintaining consistent study-wide safeguards. The solution drew on lessons from a previously completed study with similar design characteristics and was implemented before site activation and patient enrollment. The Vantage BioTrials Solution From protocol requirement to executable site controls 1\u00a0 Risk and workflow mapping \u00b7\u00a0\u00a0 Mapped every point where treatment allocation or concentration data could become visible. \u00b7\u00a0\u00a0 Assessed pharmacy, laboratory, electronic access and communication workflows. \u00b7\u00a0\u00a0 Defined which roles required unblinded access and which had to remain protected. 2\u00a0 Customized operating model \u00b7\u00a0\u00a0 Created site-specific blinding plans aligned with institutional requirements. \u00b7\u00a0\u00a0 Established separate blinded and unblinded roles, access controls and communication pathways. \u00b7\u00a0\u00a0 Defined escalation procedures for potential or emergency unblinding situations. 3\u00a0 Pre-enrollment implementation \u00b7\u00a0\u00a0 Assigned dedicated unblinded monitors for activities capable of revealing treatment allocation. \u00b7\u00a0\u00a0 Trained relevant site and monitoring personnel before enrollment. \u00b7\u00a0\u00a0 Verified that every participating center had functional controls in place before enrolling participants. 4\u00a0 Ongoing oversight \u00b7\u00a0\u00a0 Monitored drug dispensing, dosing, storage and accountability. \u00b7\u00a0\u00a0 Reviewed therapeutic drug monitoring processes for continued separation. \u00b7\u00a0\u00a0 Reconciled used and unused supplies and maintained traceable, inspection-ready documentation. Measurable outcomes 0 documented unblinding events 0 blinding-related protocol deviations 100% of centers had controls verified before enrollment 100% of drug accountability records reconciled without compromising the blind The strategy allowed sites to meet therapeutic drug monitoring requirements while maintaining a clear separation between blinded and unblinded activities. By resolving the vulnerability before enrollment, the sponsor avoided the need for reactive remediation, retrospective impact assessments and potential questions regarding the usability of affected participant data. Why This Matters to Sponsors Lean biotech teams depend on their CRO to identify risks that are not fully resolved by protocol language. VBT does not wait for an issue to become a deviation before addressing it. By bringing senior clinical operations and quality expertise into study planning, VBT helps sponsors translate complex protocols into practical operating models that sites can execute consistently. YOUR\u00a0 ADVANTAGE Senior-level involvement \u2022 Customized solutions \u2022 Quality by Design integrated into clinical operations \u2022 Controls adapted to real site workflows \u2022 Early intervention before risks affect patients, timelines or data Is your protocol operationally executable at every site? Contact Vantage BioTrials about your upcoming clinical program. Case Study 3: How Patient-Journey Mapping Protected Eligibility in a Phase II Acute Variceal Bleeding Trial The Challenge A biotechnology sponsor conducting a Phase II trial in\u00a0patients with acute variceal bleeding faced a significant enrollment and evaluability risk. Because patients required urgent medical intervention,\u00a0potentially eligible participants frequently entered the hospital through emergency departments or other acute-care units. By the time the research team was notified, medically necessary non-study therapies may already have been administered, making the patient ineligible under the protocol. The underlying risk was therefore not limited to recruitment performance. It existed within the patient\u2019s journey through the hospital, before the individual reached the research team. The Operational Insight Vantage BioTrials mapped how potential participants moved through emergency medicine, gastroenterology, hepatology, critical care, and research services. This assessment identified the critical failure point: the interval between initial presentation, clinical assessment, treatment decisions, and notification of study personnel. Rather than relying solely on conventional site\u00a0recruitment tactics, VBT developed a cross-department strategy designed to enable earlier identification and rapid research-team notification where\u00a0clinically appropriate, without delaying or interfering with necessary patient care. The Vantage BioTrials Approach Vantage BioTrials implemented four integrated operational controls: Strategic site selectionSites were evaluated not only on access to eligible patients but also on their\u00a0ability to coordinate care and communicate across the clinical departments\u00a0involved in the patient pathway. Cross-department trainingTraining extended beyond investigators and study coordinators to emergency department personnel and other frontline healthcare professionals involved in\u00a0initial patient assessment and treatment. Site-specific referral pathwaysEach site developed a customized plan defining patient-identification procedures, escalation pathways, departmental responsibilities, and rapid\u00a0notification processes. Point-of-care eligibility toolsConcise reference cards summarized critical eligibility criteria and provided direct contact information for study coordinators and investigators. These\u00a0tools were distributed across relevant departments to support timely identification and referral. All training and site-specific referral plans\u00a0were completed before the applicable sites began enrollment. The Outcome 100%\u00a0of participating sites completed eligibility and referral-pathway training before activation. 100%\u00a0of participating sites implemented site-specific referral plans before enrolling their first patient. Zero major protocol deviations related to eligibility or administration of protocol-disqualifying therapies were reported during study conduct. The\u00a0approach established consistent operational controls across [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"iawp_total_views":426,"footnotes":""},"class_list":["post-52","page","type-page","status-publish","hentry","cms-no-post-thumbnail"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"CASE STUDIES Let Vantage BioTrials\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. All of our case-studies are real life situations which can serve as valuable examples in creating training tools for your needs. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial VBT was\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/vantagebiotrials.com\/fr\/case-studies\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_CA\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Vantage Biotrials - Contract Research Organization (CRO) implementing Risk-Based Management through the use of Quality by Design (Qbd) methodologies.\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Case Studies - Vantage Biotrials\" \/>\n\t\t<meta property=\"og:description\" content=\"CASE STUDIES Let Vantage BioTrials\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. All of our case-studies are real life situations which can serve as valuable examples in creating training tools for your needs. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial VBT was\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/vantagebiotrials.com\/fr\/case-studies\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2023\/11\/logo-post.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2023\/11\/logo-post.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"305\" \/>\n\t\t<meta property=\"og:image:height\" content=\"130\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-08-22T02:05:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-08-13T18:53:43+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@VantageBT\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Case Studies - Vantage Biotrials\" \/>\n\t\t<meta name=\"twitter:description\" content=\"CASE STUDIES Let Vantage BioTrials\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. All of our case-studies are real life situations which can serve as valuable examples in creating training tools for your needs. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial VBT was\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@VantageBT\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2023\/11\/logo-post.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/case-studies\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/case-studies\\\/#listItem\",\"name\":\"Case Studies\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/case-studies\\\/#listItem\",\"position\":2,\"name\":\"Case Studies\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr#listItem\",\"name\":\"Home\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/#organization\",\"name\":\"Vantage Biotrials\",\"description\":\"Contract Research Organization (CRO) implementing Risk-Based Management through the use of Quality by Design (Qbd) methodologies.\",\"url\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/\",\"telephone\":\"+15145643466\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/vantagebiotrials.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/logo-post.png\",\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/case-studies\\\/#organizationLogo\",\"width\":305,\"height\":130},\"image\":{\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/case-studies\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/VantageBT\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/vantage-biotrials-inc-\"]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/case-studies\\\/#webpage\",\"url\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/case-studies\\\/\",\"name\":\"Case Studies - Vantage Biotrials\",\"description\":\"CASE STUDIES Let Vantage BioTrials\\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. All of our case-studies are real life situations which can serve as valuable examples in creating training tools for your needs. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial VBT was\",\"inLanguage\":\"fr-CA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/case-studies\\\/#breadcrumblist\"},\"datePublished\":\"2023-08-22T02:05:00+00:00\",\"dateModified\":\"2026-08-13T18:53:43+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/\",\"name\":\"Vantage Biotrials\",\"description\":\"Contract Research Organization (CRO) implementing Risk-Based Management through the use of Quality by Design (Qbd) methodologies.\",\"inLanguage\":\"fr-CA\",\"publisher\":{\"@id\":\"https:\\\/\\\/vantagebiotrials.com\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Case Studies - Vantage Biotrials","description":"CASE STUDIES Let Vantage BioTrials\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. All of our case-studies are real life situations which can serve as valuable examples in creating training tools for your needs. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial VBT was","canonical_url":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/vantagebiotrials.com\/fr#listItem","position":1,"name":"Home","item":"https:\/\/vantagebiotrials.com\/fr","nextItem":{"@type":"ListItem","@id":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/#listItem","name":"Case Studies"}},{"@type":"ListItem","@id":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/#listItem","position":2,"name":"Case Studies","previousItem":{"@type":"ListItem","@id":"https:\/\/vantagebiotrials.com\/fr#listItem","name":"Home"}}]},{"@type":"Organization","@id":"https:\/\/vantagebiotrials.com\/fr\/#organization","name":"Vantage Biotrials","description":"Contract Research Organization (CRO) implementing Risk-Based Management through the use of Quality by Design (Qbd) methodologies.","url":"https:\/\/vantagebiotrials.com\/fr\/","telephone":"+15145643466","logo":{"@type":"ImageObject","url":"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2023\/11\/logo-post.png","@id":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/#organizationLogo","width":305,"height":130},"image":{"@id":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/#organizationLogo"},"sameAs":["https:\/\/x.com\/VantageBT","https:\/\/www.linkedin.com\/company\/vantage-biotrials-inc-"]},{"@type":"WebPage","@id":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/#webpage","url":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/","name":"Case Studies - Vantage Biotrials","description":"CASE STUDIES Let Vantage BioTrials\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. All of our case-studies are real life situations which can serve as valuable examples in creating training tools for your needs. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial VBT was","inLanguage":"fr-CA","isPartOf":{"@id":"https:\/\/vantagebiotrials.com\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/#breadcrumblist"},"datePublished":"2023-08-22T02:05:00+00:00","dateModified":"2026-08-13T18:53:43+00:00"},{"@type":"WebSite","@id":"https:\/\/vantagebiotrials.com\/fr\/#website","url":"https:\/\/vantagebiotrials.com\/fr\/","name":"Vantage Biotrials","description":"Contract Research Organization (CRO) implementing Risk-Based Management through the use of Quality by Design (Qbd) methodologies.","inLanguage":"fr-CA","publisher":{"@id":"https:\/\/vantagebiotrials.com\/fr\/#organization"}}]},"og:locale":"fr_CA","og:site_name":"Vantage Biotrials - Contract Research Organization (CRO) implementing Risk-Based Management through the use of Quality by Design (Qbd) methodologies.","og:type":"article","og:title":"Case Studies - Vantage Biotrials","og:description":"CASE STUDIES Let Vantage BioTrials\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. All of our case-studies are real life situations which can serve as valuable examples in creating training tools for your needs. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial VBT was","og:url":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/","og:image":"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2023\/11\/logo-post.png","og:image:secure_url":"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2023\/11\/logo-post.png","og:image:width":305,"og:image:height":130,"article:published_time":"2023-08-22T02:05:00+00:00","article:modified_time":"2026-08-13T18:53:43+00:00","twitter:card":"summary_large_image","twitter:site":"@VantageBT","twitter:title":"Case Studies - Vantage Biotrials","twitter:description":"CASE STUDIES Let Vantage BioTrials\u2019 vast industry experience guide you in making an informed decision about how to conduct your clinical trials. All of our case-studies are real life situations which can serve as valuable examples in creating training tools for your needs. Case Study 1: Competing Studies For a Phase III Infectious Disease Trial VBT was","twitter:creator":"@VantageBT","twitter:image":"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2023\/11\/logo-post.png"},"aioseo_meta_data":{"post_id":"52","title":null,"description":null,"keywords":null,"keyphrases":{"focus":[],"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2025-09-27 12:54:50","updated":"2026-08-18 04:15:33","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/vantagebiotrials.com\/fr\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tCase Studies\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/vantagebiotrials.com\/fr"},{"label":"Case Studies","link":"https:\/\/vantagebiotrials.com\/fr\/case-studies\/"}],"_links":{"self":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/pages\/52","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/comments?post=52"}],"version-history":[{"count":63,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/pages\/52\/revisions"}],"predecessor-version":[{"id":5449,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/pages\/52\/revisions\/5449"}],"wp:attachment":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/media?parent=52"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}